Loading…
Time matters - in vitro cellular disposition kinetics help rationalizing cellular potency disconnects
Loss in potency is commonly observed in early drug discovery when moving from biochemical to more complex cellular systems. Among other factors, low permeability is often considered to cause such potency disconnects. We developed a novel cellular disposition assay in MDCK cells to determine passive...
Saved in:
Published in: | Xenobiotica 2022-08, Vol.52 (8), p.878-889 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Loss in potency is commonly observed in early drug discovery when moving from biochemical to more complex cellular systems. Among other factors, low permeability is often considered to cause such potency disconnects.
We developed a novel cellular disposition assay in MDCK cells to determine passive uptake clearance (PS
inf
), cell-to-medium ratios at steady-state (K
p
) and the time to reach 90% steady-state (TTSS
90
) from a single experiment in a high-throughput format.
The assay was validated using 40 marketed drugs, showing a wide distribution of PS
inf
and K
p
values. The parameters generally correlated with transcellular permeability and lipophilicity, while PS
inf
data revealed better resolution in the high and low permeability ranges compared to traditional permeability data. A linear relationship between the K
p
/PS
inf
ratio and TTSS
90
was mathematically derived and experimentally validated, demonstrating the dependency of TTSS
90
on the rate and extent of cellular accumulation.
Cellular disposition parameters could explain potency (IC
50
) disconnects noted for seven Bruton's tyrosine kinase degrader compounds in a cellular potency assay. In contrast to transcellular permeability, PS
inf
data enabled identification of the compounds with IC
50
disconnects based on their time to reach equilibrium. Overall, the novel assay offers the possibility to address potency disconnects in early drug discovery. |
---|---|
ISSN: | 0049-8254 1366-5928 |
DOI: | 10.1080/00498254.2022.2130837 |